Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 360 publications

Multidisciplinary management of solitary hypervascular metastatic recurrence of renal cell carcinoma presenting with pathological femoral fracture.

Condition: Metastatic Recurrence of Renal Cell Carcinoma (RCC) with Femoral Fracture
Journal: BMJ case reports
Treatment Used: Transarterial Emobolization. Surgical Resection, and Megaprosthesis Implantation
Number of Patients: 1
Published: November 10, 2021
View publication
Summary: This case report describes a 46-year-old male patient with solitary hypervascular metastatic recurrence of renal cell carcinoma with femoral fracture treated with transarterial embolization, surgical resection, and implantation of a megaprosthesis.

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.

Condition: Metastatic Kidney Cancer
Journal: Clinical & experimental metastasis
Treatment Used: Stereotactic Body Radiotherapy
Number of Patients: 207
Published: November 08, 2021
View publication
Summary: This study tested the safety and efficacy of using stereotactic body radiotherapy to treat patients with metastatic kidney cancer.

Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials.

Condition: Advanced Renal Cell Carcinoma (RCC)
Journal: Clinical immunology (Orlando, Fla.)
Treatment Used: Immune Checkpoint Inhibitor Combination Therapy
Number of Patients: 3461
Published: November 06, 2021
View publication
Summary: The aim of the study was to evaluate the effectiveness and safety of immune checkpoint inhibitor combination therapy in advanced renal cell carcinoma (RCC).

Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.

Condition: Hemodialysis Patients with Metastatic Renal Cell Carcinoma (mRCC)
Journal: In vivo (Athens, Greece)
Treatment Used: Nivolumab Plus Ipilimumab Therapy
Number of Patients: 3
Published: October 26, 2021
View publication
Summary: This study evaluated the safety and effectiveness of nivolumab-ipilimumab combination therapy in the treatment of patients on hemodialysis with metastatic renal cell carcinoma (mRCC).

Risk factors for the development of postoperative complications in patients with metastatic kidney cancer treated with cytoreductive nephrectomy.

Condition: Metastatic Kidney Cancer
Journal: Cirugia y cirujanos
Treatment Used: Cytoreductive Nephrectomy
Number of Patients: 67
Published: October 19, 2021
View publication
Summary: This study tested the safety and efficacy of using cytoreductive nephrectomy to treat patients with metastatic kidney cancer.

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.

Condition: Myocarditis Following Treatment with Ipilimumab and Nivolumab Combination Therapy for Metastatic Renal Cell Carcinoma
Journal: Journal of medical case reports
Treatment Used: Steroid Therapy
Number of Patients: 1
Published: October 15, 2021
View publication
Summary: This case report describes a 71-year-old Asian man diagnosed with myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma.

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.

Condition: Immune-Related Adverse Events
Journal: Molecules (Basel, Switzerland)
Treatment Used: Systemic Steroids
Number of Patients: 146
Published: October 13, 2021
View publication
Summary: The aim of this study was to evaluate the use of systemic steroid to treat immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors.

Chromophobe Renal Cell Carcinoma of a Renal Allograft.

Journal: The American journal of case reports
Published: October 08, 2021
View publication
Summary: Chromophobe Renal Cell Carcinoma of a Renal Allograft.

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.

Condition: Metastatic Renal Cell Carcinoma (mCRC)
Journal: Cancer treatment reviews
Treatment Used: VEGFR-TKIs Plus Immune Checkpoint Inhibitors
Number of Patients: 0
Published: September 26, 2021
View publication
Summary: This review of the literature evaluated the effectiveness of VEGFR-TKIs plus immune checkpoint inhibitors in the treatment of patients with metastatic renal cell carcinoma (mCRC).

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events.

Condition: Advanced Solid Tumors
Journal: Oncology research and treatment
Treatment Used: HKT288, CDH6-Targeting Antibody-Drug Conjugate
Number of Patients: 9
Published: September 13, 2021
View publication
Summary: This study evaluated the tolerability, safety, and effectiveness of HKT288, a CDH6-targeting antibody-drug conjugate (ADC), in the treatment of patients with advanced solid tumors.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Condition: Kidney Cancer
Journal: The New England journal of medicine
Treatment Used: Pembrolizumab
Number of Patients: 496
Published: August 18, 2021
View publication
Summary: The study researched the use of pembrolizumab for treating patients with kidney cancer.

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).

Condition: Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
Journal: Current oncology (Toronto, Ont.)
Treatment Used: Surgery and Combination Pembrolizumab and Axitinib
Number of Patients: 1
Published: July 02, 2021
View publication
Summary: This case report describes an 18-year-old male with hereditary leyomiomatosis (muscle tumors) and renal (kidney) cell cancer (HLRCC) treated with surgery and a combination of pembrolizumab and axitinib.
Showing 1-12 of 360